The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immunotherapy engagement in pancreatic adenocarcinoma: Provisional results of iLSTA study— Durvalumab, LSTA1 (certepetide), gemcitabine, and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma.
 
Andrew Dean
Leadership - Valo Therapeutics
Stock and Other Ownership Interests - A2A Pharmaceuticals
Honoraria - Amgen; Juniper Pharmaceuticals
Speakers' Bureau - Juniper Biologics
Travel, Accommodations, Expenses - Juniper Biologics; Juniper Biologics; Novartis
(OPTIONAL) Uncompensated Relationships - A2A Pharmaceuticals
 
Mikael Johansson
No Relationships to Disclose
 
Ian Yusoff
No Relationships to Disclose
 
Samarth Rao
No Relationships to Disclose
 
Susan Sparrow
No Relationships to Disclose
 
Priyanthi Kumarasinghe
No Relationships to Disclose
 
Suresh Navadgi
No Relationships to Disclose
 
Yuki Watanabe
No Relationships to Disclose
 
Laurence Webber
No Relationships to Disclose
 
Jenny Grew
No Relationships to Disclose
 
Shane Fitzgerald
No Relationships to Disclose
 
Olivia Comito
No Relationships to Disclose